tafenoquine + atovaquone

"tafenoquine + atovaquone" is an investigational combination therapy consisting of the 8-aminoquinoline antimalarial tafenoquine (marketed under the brand name Arakoda) and the anti-parasitic drug atovaquone. The combination is being evaluated for the treatment of human babesiosis, a tick-borne parasitic disease caused by intraerythrocytic *Babesia* parasites (such as *Babesia microti* and *Babesia duncani*). In preclinical mouse models, the combination has demonstrated the ability to achieve radical cure and clear infections with no recrudescence, even against atovaquone-resistant strains, while also conferring sterile immunity against subsequent challenge. 60 Degrees Pharmaceuticals is investigating tafenoquine-containing regimens, including combinations with atovaquone, in clinical trials for relapsing, treatment-refractory babesiosis.

Other names

Arakoda + atovaquonetafenoquine and atovaquonetafenoquine plus atovaquone